BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 95813)

  • 1. Evidence for glomerular modulation of complement activation.
    Moseley HL; Whaley K
    J Clin Lab Immunol; 1979 Apr; 2(1):9-13. PubMed ID: 95813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of complement activation in membranous and membranoproliferative glomerulonephritis.
    Moseley HL; Whaley K
    Kidney Int; 1980 Apr; 17(4):535-44. PubMed ID: 6446614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative importance of C3b inactivator and beta 1H globulin in the modulation of the properdin amplification loop in systemic lupus erythematosus.
    Whaley K; Schur PH; Ruddy S
    Clin Exp Immunol; 1979 Jun; 36(3):408-14. PubMed ID: 114347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of the properdin amplification loop in membranoproliferative and other forms of glomerulonephritis.
    Whaley K; Ward D; Ruddy S
    Clin Exp Immunol; 1979 Jan; 35(1):101-6. PubMed ID: 85507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement inhibitors in normal cornea and aqueous humor.
    Mondino BJ; Sumner H
    Invest Ophthalmol Vis Sci; 1984 Apr; 25(4):483-6. PubMed ID: 6706511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement deposition in glomerular diseases.
    di Belgiojoso GB; Tarantino A; Durante A; Guerra L
    Proc Eur Dial Transplant Assoc; 1975; 11():515-21. PubMed ID: 1105561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement receptor binding of C3b-coated cells treated with C3b inactivator, beta 1H globulin and trypsin.
    Carlo JR; Ruddy S; Studer EJ; Conrad DH
    J Immunol; 1979 Aug; 123(2):523-8. PubMed ID: 88474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-independent activation of C1. II. Evidence for two classes of nonimmune activators of the classical pathway of complement.
    Peitsch MC; Kovacsovics TJ; Tschopp J; Isliker H
    J Immunol; 1987 Mar; 138(6):1871-6. PubMed ID: 3029223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C1 inactivator and C3b inactivator in peripheral lymph of normal men.
    Olszewski WL; Lukomska B; Engeset A
    Arch Immunol Ther Exp (Warsz); 1982; 30(1-2):79-86. PubMed ID: 7149928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor.
    Veerhuis R; Janssen I; De Groot CJ; Van Muiswinkel FL; Hack CE; Eikelenboom P
    Exp Neurol; 1999 Nov; 160(1):289-99. PubMed ID: 10630213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunopathology of the end-stage kidney. Immunoglobulin and complement component deposition in nonimmune disease.
    Velosa J; Miller K; Michael AF
    Am J Pathol; 1976 Jul; 84(1):149-62. PubMed ID: 779494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunofluorescence studies of dense deposit disease. The presence of railroad tracks and mesangial rings.
    Kim Y; Vernier RL; Fish AJ; Michael AF
    Lab Invest; 1979 Apr; 40(4):474-80. PubMed ID: 372673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glomerular deposition of complement-control proteins in acute and chronic glomerulonephritis.
    Wyatt RJ; McAdams AJ; Forristal J; Snyder J; West CD
    Kidney Int; 1979 Oct; 16(4):505-12. PubMed ID: 398417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-independent activation of C1. I. Differences in the mechanism of C1 activation by nonimmune activators and by immune complexes: C1r-independent activation of C1s by cardiolipin vesicles.
    Kovacsovics TJ; Peitsch MC; Kress A; Isliker H
    J Immunol; 1987 Mar; 138(6):1864-70. PubMed ID: 3029222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro fixation of guinea pig complement by renal biopsies.
    Uff JS; Evans DJ; Bartolotti SR
    J Clin Lab Immunol; 1979 Feb; 1(4):299-304. PubMed ID: 387964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
    Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
    Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative pathway complement activation in rheumatoid arthritis.
    El-Ghobarey A; Whaley K
    J Rheumatol; 1980; 7(4):453-60. PubMed ID: 6158571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The alternate complement pathway. A possible role in a patient with focal glomerular sclerosis.
    Stapleton FB; Linshaw MA; Cuppage FE; Kim YK; Quie PG
    Arch Pathol Lab Med; 1981 Mar; 105(3):160-3. PubMed ID: 6894082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Studies of complement, nephritic factor, and circulating immune complexes in chronic mesangiocapillary glomerulonephritis types I and II (author's transl)].
    Mirapeix E; Yagüe J; Vives J; Revert L
    Med Clin (Barc); 1981 Jun; 77(1):21-6. PubMed ID: 7253758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunofluorescence patterns in chronic membranoproliferative glomerulonephritis (MPGN).
    Belgiojoso GB; Tarantino A; Bazzi C; Colasanti G; Guerra L; Durante A
    Clin Nephrol; 1976 Jul; 6(1):303-10. PubMed ID: 782750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.